Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PurposeTo investigate antimicrobial combinations for synergy or antagonism against isolates of Staphylococcus aureus and Pseudomonas aeruginosa.MethodsIsolates were collected from cases of microbial keratitis from six centers in the United Kingdom. Minimum inhibitory concentrations (MICs) were determined by using E-test strips for 16 antimicrobials, including both current and potentially available agents. E-test strips were used to test selected antimicrobials in combination against a representative set of 10 S. aureus and 10 P. aeruginosa isolates. E-tests of the two antimicrobials were placed on sensitivity agar at right angles intersecting at their respective MICs. Antimicrobial combinations were classified as synergistic, additive, indifferent, or antagonistic, according to their fractional inhibitory concentration (FIC).ResultsThe combinations meropenem and ciprofloxacin, meropenem and teicoplanin, moxifloxacin and teicoplanin, and ciprofloxacin and teicoplanin, gave the lowest mean FICs for S. aureus, with synergy or additivity being seen in 60% to 80% of isolates. The meropenem/ciprofloxacin combination gave the lowest mean FIC for P. aeruginosa isolates, with 90% showing an additive or synergistic effect. The other combinations elicited a predominantly indifferent response. No consistent antagonistic effect was observed with the combinations used.ConclusionsThe combination of meropenem and ciprofloxacin was predominantly additive or synergistic for both S. aureus and P. aeruginosa. Teicoplanin combined with meropenem, ciprofloxacin, or moxifloxacin was also predominantly additive or synergistic against S. aureus.

More information Original publication

DOI

10.1167/iovs.09-4839

Type

Journal article

Publication Date

2010-08-01T00:00:00+00:00

Volume

51

Pages

4151 - 4155

Total pages

4

Addresses

D, e, p, a, r, t, m, e, n, t, , o, f, , O, p, h, t, h, a, l, m, o, l, o, g, y, ,, , R, o, y, a, l, , L, i, v, e, r, p, o, o, l, , U, n, i, v, e, r, s, i, t, y, , H, o, s, p, i, t, a, l, ,, , L, i, v, e, r, p, o, o, l, ,, , U, K, ., , h, s, u, e, k, e, @, g, m, a, i, l, ., c, o, m

Keywords

Humans, Pseudomonas aeruginosa, Staphylococcus aureus, Corneal Ulcer, Drug Combinations, Anti-Bacterial Agents, Microbial Sensitivity Tests, Drug Antagonism, Drug Synergism, Drug Resistance